Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18768831 | 0.86 | HIF1A (0.41) | HIF1A | |
| SCHEMBL17613220 | 0.86 | HIF1A (0.41) | HIF1A | |
| SCHEMBL23130636 | 0.86 | HIF1A (0.41) | HIF1A | |
| SCHEMBL11990606 | 0.86 | HIF1A (0.41) | HIF1A | |
| SCHEMBL17613231 | 0.86 | HIF1A (0.41) | HIF1A | |
| SCHEMBL25779301 | 0.85 | HIF1A (0.35) | HIF1A | |
| SCHEMBL3955608 | 0.83 | — | — | |
| SCHEMBL13541741 | 0.79 | — | — | |
| SCHEMBL18210931 | 0.79 | HIF1A (0.32) | HIF1A | |
| SCHEMBL10249614 | 0.79 | CA2 (0.39) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11160871-B2 | SSTR-targeted conjugates and particles and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-2793947-B1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2021-02-03 | — | — | EP | disclosed |
| US-10322191-B2 | Targeted conjugates and particles and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180221499-A1 | SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2018-08-09 | — | — | US | disclosed |
| US-20170312245-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2017-11-02 | — | — | US | disclosed |
| US-9486535-B2 | Methods of making and using nanostructures | TYCHON BIOSCIENCE, LLC (US) | 2016-11-08 | — | — | US | disclosed |
| US-9486535-B2 | Methods of making and using nanostructures | TYCHON BIOSCIENCE, LLC (US) | 2016-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221499-A1 | SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR1, SSTR4, SSTR3 | HIF1A 1469/4885 |
| US-10322191-B2 | Targeted conjugates and particles and formulations thereof | SSTR5, SSTR1, SSTR4 | HIF1A 1525/4885 |
| US-11160871-B2 | SSTR-targeted conjugates and particles and formulations thereof | SSTR1, SSTR4, SSTR3 | HIF1A 1469/4885 |
| US-20170312245-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR5, SSTR1, SSTR4 | HIF1A 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.